The Cautionary Tale

A ban with no borders: how each country tried to stop Melanotan II

By Tan Lines·Published September 24, 2026

Ask “is Melanotan II legal?” and you get a lawyer’s answer: it depends where you stand, and on which verb — making, selling, advertising, buying, holding. What doesn’t depend on geography is the underlying fact. In no major market is the peptide an approved medicine. Every regulator that has looked at it reached the same verdict. What differed — and what makes the story worth mapping — is the weapon each one chose, and the fact that none of the weapons worked.

This is the enforcement map: the same unapproved drug, five regulators, one outcome. Read alongside what the warnings actually did, it is a case study in why a borderless, socially-transmitted market is so hard for border-bound agencies to stop.

United Kingdom — the earliest, loudest campaign

The MHRA moved first and stayed at it longest. In November 2008 it issued a public warning and wrote to eighteen companies telling them, in plain terms, that advertising or supplying Melanotan was illegal — it had never been through the medicines-authorisation process, so putting it on sale broke the law before any question of safety even arose. That was the opening shot of the gray-market era in Britain.

The MHRA didn’t stop at letters. By 2014 it reported working with internet service providers at home and abroad to suspend more than 100 websites illegally trading in Melanotan. This is the most aggressive posture of any of the agencies here — treat the sellers as the target, go after the infrastructure, keep going for years.

It is also the clearest demonstration of the limit. A hundred suppressed sites did not end UK supply; it moved, re-hosted, and by the late 2010s migrated onto the influencer channels that no website-takedown regime was built to touch.

Australia — the fine as the instrument

Australia’s TGA reached for money. In its most concrete action it issued 27 infringement notices totalling A$101,412 to a single New South Wales individual for unlawfully supplying Melanotan II in breach of the Therapeutic Goods Act 1989 — penalties that were paid in May 2026. Alongside the enforcement it ran public warnings (a prominent one in 2025) spelling out the health risks of tanning products containing melanotan.

The Australian approach is instructive precisely because it is so tangible: a named supplier, a specific sum, a paid penalty. And still it is one supplier. The fine punishes an actor; it does not close the channel. That is the recurring shape of gray-market enforcement — real consequences for the unlucky or high-volume seller, no dent in aggregate availability.

Ireland — the ad-removal war

Ireland’s HPRA fought the market where it now actually lives: the feed. In June 2022 it issued a public alert warning that Melanotan is an unauthorised substance posing serious health risks and telling consumers not to buy it. The striking figure is the scale of its takedown effort — between January 2020 and June 2022 the HPRA ordered the removal of more than 500 social-media or e-commerce advertisements for these products.

Five hundred ads in thirty months is the honest measure of the modern market’s metabolism. It also names the newer battlefield. The fight is no longer over rogue pharmacy sites; it is over Instagram posts, marketplace listings, and DMs — a volume game an agency can wade into but never win, because supply is now woven into a wellness culture that manufactures new listings faster than any takedown queue can clear them.

United States — the quiet wall of “unapproved”

The FDA’s approach is the least dramatic and, in its own way, the most total. It never needed a bespoke Melanotan campaign because the drug fails at the threshold: it is an unapproved new drug, which makes its interstate sale and marketing unlawful and subjects it to import controls at the border. There is no approved Melanotan II product to prescribe, compound-for-tanning, or import for cosmetic use. (The distinction that matters — the approved melanocortin drugs that did come through the front door — is the subject of the three doors.)

The American wall is passive but high: no approval means no legitimate channel at all. Yet the same cross-border e-commerce reality that defeated the UK’s takedowns routes around a border-control posture too, which is why “unapproved” and “widely available” have coexisted in the US for the entire period.

Why the map has no borders

Lay the five approaches side by side — letters and site-suspensions (UK), fines (Australia), ad-removals (Ireland), import controls (US), the shared EU stance of non-authorisation — and the pattern is unmistakable. Every tool that exists has been used by someone, and the product is still a search away in all of them.

The reason isn’t regulatory laziness; it’s a structural mismatch. Enforcement agencies are organised around borders, licensed sellers, and physical supply chains. The Melanotan market is organised around none of those things — it is peer-to-peer, platform-hosted, socially endorsed, and indifferent to jurisdiction. You can fine the seller you can find and suppress the site you can see. You cannot subpoena the demand, and the demand — as the culture pillar of this record argues — is the part that was never really about the vial.

That is the sober conclusion of the map. The verdict on Melanotan II has been unanimous and unbroken for the better part of two decades. The enforcement has been genuine, sometimes forceful, occasionally expensive for the people caught. And it has changed the supply’s shape far more than its size. A ban only works where there’s a border to enforce it on. This market never had one.